Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 7/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.37 |
| ▸ | CDK4 | P11802 | 4/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL657216 | 0.89 | CDK2 (0.37) | CDK2CCNE1CDK4HDAC6HDAC1 | |
| SCHEMBL3357662 | 0.89 | CDK2 (0.50) | CDK2CCNE1CDK4HDAC1 | |
| SCHEMBL659860 | 0.87 | HDAC1 (0.51) | CDK2CCNE1CDK4HDAC6HDAC1 | |
| SCHEMBL3348358 | 0.79 | CDK2 (0.52) | CDK2CCNE1CDK4HDAC1 | |
| SCHEMBL3349942 | 0.77 | HDAC1 (0.62) | CDK2CCNE1CDK4HDAC1 | |
| SCHEMBL655677 | 0.76 | CCNE1 (0.33) | CDK2CCNE1CDK4HDAC6HDAC1 | |
| SCHEMBL659399 | 0.76 | CCNE1 (0.33) | CDK2CCNE1CDK4HDAC6HDAC1 | |
| SCHEMBL658497 | 0.76 | CDK4 (0.36) | CDK2CCNE1CDK4HDAC6HDAC1 | |
| SCHEMBL655847 | 0.76 | HDAC1 (0.49) | CDK2CCNE1CDK4HDAC6HDAC1 | |
| SCHEMBL657000 | 0.76 | HDAC1 (0.43) | CDK2HDAC6HDAC1HDAC2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120045412-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-02-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120045412-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC2 | CDK2 213/4885CCNE1 1992/4885CDK4 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.